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a period of 36 months of which six were emergencies. The mean age was 64.6 years.
26 patients were ASA Grade III or more.
Methods: Risk factors were hypertension (n=20), hypercholesterolaemia (n= 17),
smoking (n=14) and ischaemic heart disease (n=9). 17 procedures were for thoracic
abdominal aneurysms type three, 7 thoraco-abdominal aneurysms type four, 4 aortic
dissection Type B, 1 infantile adult aortic coarctation and 2 spontaneous supra visceral
aortic ruptures. Seven patients underwent a one/ two stage hybrid debranching of
visceral vessels followed by TEVAR. Fourteen patients underwent chimney or Snorkel
Endografting of Subclavian or renal vessels. Two patients underwent multilayered
stenting for thoraco-abdominal aneurysms with visceral involvement. One patient had
a CPS stent for infantile adult coarctation.
Results: Primary endpoints were 6% mortalities within 30 days for the two acute
emergencies of which one was a HIV patient with syphilitic aneurysm. 30 day
morbidity was one acute tubular necrosis and one lower respiratory tract infection.
Aneurysm free survival time was 19months. No patients developed aneurysm rupture,
paraplegia or stroke. Four cases of endoleak were witnessed however no aneurysm
expansion was experienced. Two patients required re-intervention for graft migration.
Conclusion: We display from our experience that minimal invasive techniques with
TEVAR and debranching, chimney, snorkel and multilayered stent grafting of visceral
vessels is safe, prudent and economically viable. The development of multilayered
stenting technique looks ever promising for future management of complex aortic
pathologies.
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Background: Restenosis remains the primary limitation following femoropopliteal
PTA, with rates of 40 - 60% at 1 year. Multiple prospective, randomized studies
(FemPac, THUNDER) evaluated the concept of localized antiproliferative drug
delivery for the prevention of restenosis in the peripheral arteries using Paccocath®
paclitaxel coated balloons versus uncoated balloons. These studies demonstrated
favorable results for the Paccocath balloon cohort on late lumen loss (LLL) and target
lesion revascularization (TLR) rates up to 2 years post index procedure. The purpose
of this study is to assess long term efficacy results of the Paccocath balloon versus an
uncoated balloon.
Methods: Patients who were originally enrolled and treated in the THUDNER trial
were re-consented to enable the 5-year follow-up data collection. The clinical data
(e.g., TLR, deaths, amputations, bypass surgery, etc.) and angiograms were collected
up to 5 years follow-up. The 5-year clinical and angiographic data analyzed by an
independent angiographic core laboratory were compared to the previously reported
baseline, 6, 12, and 24 months data to assess the long-term effect of the Paccocath
balloon.
Results: The data is currently being monitored. However, the preliminary analysis
demonstrated that TLR rates are significantly lower in the Paccocath balloon group
compared to the uncoated balloon group. As confirmed by 5-year follow-up visits,
approximately 70% of patients in the Paccocath balloon group did not require any
additional target lesion treatment (e.g., TLR) from the time of the index procedure
compared to approximately 30% of patients in the uncoated balloon group. In addition,
the time to the first TLR from the index procedure is significantly longer in the
Paccocath balloon group compared to the uncoated balloon group. Besides clinical and
angiographic data, the finding that severe dissections left with no stent implantation in
the Paccocath group was a predictor of favorable long term outcomes will be presented
at TCT 2011.
Conclusion: The Paccocath balloon demonstrated superior long-term results compared
to the uncoated balloon when used for the treatment of femoropopliteal arteries.
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Background: We investigated whether the angiosome concept is useful in
endovascular therapy (EVT) of critical limb ischemia (CLI) patients with isolated
below-the-knee (BTK) lesions and assessed factors influencing major amputation (MA)
in direct and indirect groups.
Methods: We analyzed 369 limbs from 329 consecutive patients (male=224, age;
70±11 years) with ischemic ulceration/gangrene, presenting with isolated BTK lesions
(Rutherford 5: 270 limbs and 6: 99 limbs, respectively). We classified these patients
into direct (n=200) and indirect (n=169) groups depending on whether feeding artery
flow to the site of ulceration/gangrene was either successfully achieved or not based
on the angiosome concept. Rates of amputation-free survival (AFS), freedom from
major amputation (MA) and from major adverse limb events (MALE) were compared
between direct and indirect groups by Kaplan-Meier analysis and log-lank test.
Multivariate analysis was performed to explore the independent determinants of limb
salvage in the direct and indirect groups.
Results: During follow-up (mean 18±16months), the overall limb salvage rate was
81% (300/369), and death occurred in 36 % (119/329) of patients. Rates of AFS (39±7
vs. 30±7, p=.04), and freedom from MA (79±4 vs. 72±4, p=.05) and from MALE (46±6
vs. 29±8, p=.02) were significantly higher in the direct group than in the indirect group
for up to 4 years after index procedure. After multivariate Cox proportional analysis,
HbA1c (hazard ratio [HR], 1.4; 95% confidential interval [CI]: 1.1-1.9; P=0.007) and
administration of cilostazol (HR, 0.27; 95% CI, 0.11-0.68 1.1; P=0.0055) in the direct
group and C-reactive protein level (HR, 1.4; 95% CI, 1.1-1.7; P=0.001) in the indirect
group were the independent factors associated with MA by multivariate analysis.
Conclusion: Achieving direct flow by EVT based on the angiosome concept in CLI
patients with isolated BTK lesions is important for AFS, FFMA and FFMALE. Limb
salvage factors appear to differ between patients with and without direct flow from the
feeding artery after EVT.
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Background: While guidelines for the diagnosis and management of patients with
peripheral arterial disease (PAD) are well established, appropriate use of recently
introduced endovascular therapies is less defined. Clinical data from a real-world
patient population is needed to determine device utility and procedure success. The
CONFIRM Series was designed to validate the efficacy of orbital treatment in patients
with obstructive infra-inguinal disease.
Methods: The CONFIRM II Study is a prospective registry of 1,127 consecutive
patients with 1,712 infrainguinal and infrapopliteal lesions treated with the latest orbital
crown technology, Predator 360 (Cardiovascular Systems, Inc., St. Paul, MN). It
follows the CONFIRM I Study that evaluated the effectiveness of earlier device
iterations. Descriptive acute procedural data was collected by 153 investigators at 122
institutions.
Results: Patients were 70.7 years; 61.5% male. Comorbidities were renal disease
(35.4%), current or previous smokers (69.8%), diabetes (57.8%), CAD (73.2%), HTN
(91.2%), and hyperlipidemia (79.2%). Lesion morphology: mild to severe calcium
(90%). Lesion location: superficial femoral and other proximal vessels (52%), popliteal
(17%), and tibials (31%). Average lesion length: 72 mm. Device run time averaged
103 seconds per patient, followed by angioplasty (mean 5.44 atms) in 86% of lesions.
Bail-out stenting due to dissection: 2.5% of lesions. Average stenosis: 87.8% pre-
procedure, 33.9% post orbital and 9.6% post adjunctive. Procedural events included
minor and major dissection (7.8%), perforation (0.4%), slow flow (3.8%), abrupt
closure (1.4%) and distal macro embolization (1.9%).
Conclusion: The CONFIRM II Study validates the use of the latest iteration of orbital
technology in restoring flow by changing lesion compliance, thus allowing low-
pressure balloon angioplasty with limited complications and reduced need for bailout
stenting. This data contributes to a large and growing database showing predictable,
repeatable results of orbital technology in small, calcified vessels.
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Background: Current thoracic SG complies poorly with the curvature of the aortic
arch. Two new conformable SG were introduced to the European market. Due to the
different designs it is postulated, that the new SG are allowed for better apposition to
the aortic wall. We now report the first clinical experience with this technique in 45
patients.
Methods: Since 6/2009, 45 pts (33 m; 67.5(45-85)yrs) were treated for descending
thoracic aorta pathologies near the arch (TAA:27, acute dissection:9, chronic
dissection:7, trauma:2) with new thoracic SG (Zenith® TX2™Pro-Form™,n=10;
Conformable GORE TAG®,n=35). Additional arch debranching was performed in 17
cases. Evaluating the post-operative CT imaging apposition of the SG to the aortic wall
was scored (1 point (excellent): circular, 2 points (good): >2/3 circumferential, gap to
inner curve <1cm; 3 points (bad): <2/3 circumferential, gap inner curve >1cm; 4 points:
type Ia endoleak).
Results: The modified thoracic SG were correctly deployed in 42/45 pts. In one patient,
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